Professor Dr Hartwig Huland is the senior physician at the Prostate Centre at the Hamburg Eppendorf University Clinic. He founded this specialist clinic together with Professor Dr Markus Graefen in 2005.

The prostate’s function often goes unnoticed, until a malignant change occurs. What treatment options are available?

Professor Huland:

Prostate cancer is the most common malignant disease in men. The disease occurs mainly at an older age and can be treated effectively in the early stages. If the cancer has not spread, one should consider the pros and cons of radiation or surgery. Retaining potency and continence is a fundamental issue. When the prostate is irradiated, the neighbouring organs, such as the bladder or bowel are specifically not included. Therefore, continence usually remains unaffected and virility is retained in about 50 percent of patients. A surgical procedure mainly depends on the surgeon’s experience. It is very likely that the patient remains continent, and virility can be retained in about 60 to 90 percent of cases. A histological examination will show whether additional radiation therapy is required. If the prostate cancer has spread, hormone and chemotherapy will be necessary.